Sana Biotechnology, Inc. (SANA)
| Market Cap | 854.71M +66.9% |
| Revenue (ttm) | n/a |
| Net Income | -241.99M |
| EPS | -0.92 |
| Shares Out | 299.90M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,785,951 |
| Open | 2.750 |
| Previous Close | 2.680 |
| Day's Range | 2.740 - 2.900 |
| 52-Week Range | 2.430 - 6.550 |
| Beta | 2.16 |
| Analysts | Strong Buy |
| Price Target | 8.57 (+200.7%) |
| Earnings Date | May 11, 2026 |
About SANA
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company’s product pipeline includes UP421, a HIP-modified allogeneic primary islet cell product, which is in phase 1 clinical trial to treat type 1 diabetes; SC451, a HIP-modified, stem cell derived pancreatic islet cell therap... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for SANA stock is "Strong Buy." The 12-month stock price target is $8.57, which is an increase of 200.70% from the latest price.
News
Sana Biotechnology Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
The company is advancing two major platforms: a gene-modified islet therapy for type 1 diabetes aiming for a functional cure, and an in vivo CAR T platform with first-in-human trials planned this year. Key data readouts and manufacturing scale-up are expected over the next 12–18 months.
Sana Biotechnology Transcript: Jefferies Global Healthcare Conference 2026
Two advanced platforms—hypoimmune cell therapy for type 1 diabetes and in vivo CAR T—are set for clinical trials this year, with initial human data expected within 12 months. The type 1 diabetes program targets broad patient inclusion and aims for a functional cure, while the CAR T platform focuses on durable, targeted therapies for oncology and autoimmune diseases.
Did Sana Biotechnology, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible...
Sana Biotechnology to Present at June 2026 Investor Conferences
SEATTLE, May 27, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcas...
Sana Biotechnology Announces Sale of Approximately $69 Million of Shares Through its At-the-Market (ATM) Facility
SEATTLE , May 15, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it has sold a...
Sana Biotechnology presents preclinical data for in vivo CAR T cell therapy
Sana Biotechnology (SANA) announced the presentation of preclinical data demonstrating that a surrogate SG293, an in vivo CAR T cell therapy, achieved cell-specific delivery, robust and dose-dependent...
Sana Biotechnology Transcript: Bank of America Global Healthcare Conference 2026
The session highlighted a dual focus on engineered cell therapies for Type 1 diabetes and in vivo CAR-T, with significant progress in gene-modified islet transplantation and promising preclinical CAR-T data. Key milestones for SC451 and SG293 are expected within a year.
Sana Biotechnology Presents Preclinical Data for In Vivo CAR T Cell Therapy SG293 Surrogate Demonstrating Cell-Specific Delivery, Potent CAR T Cell Generation, and Deep B Cell Depletion in NHPs
SEATTLE, May 12, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced the presentation of...
Sana Biotechnology reports Q1 non-GAAP EPS (14c), consensus (15c)
Cash, cash equivalents, and marketable securities as of March 31, 2026 were $101.1M compared to $138.4M as of December 31, 2025. The decrease of $37.3M was primarily driven by cash…
Sana Biotechnology Reports First Quarter 2026 Financial Results and Business Updates
Announced strategic collaboration with Mayo Clinic, focused on improving care in type 1 diabetes and accelerating development of SC451
Sana Biotechnology Earnings release: Q1 2026
Sana Biotechnology released its Q1 2026 earnings on May 11, 2026, summarizing the period's financial results.
Sana Biotechnology Quarterly report: Q1 2026
Sana Biotechnology has published its Q1 2026 quarterly earnings report on May 11, 2026.
Sana Biotechnology Slides: Corporate presentation
Sana Biotechnology has posted slides in relation to its latest quarterly earnings report, which was published on May 11, 2026.
Sana Biotechnology initiated with a Buy at Rodman & Renshaw
Rodman & Renshaw initiated coverage of Sana Biotechnology (SANA) with a Buy rating and $16 price target The firm, which says its target reflects “the transformative clinical validation” of the…
Sana Biotechnology to Present at the BofA Securities 2026 Healthcare Conference
SEATTLE, May 05, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcas...
Sana Biotechnology Announces Oral Presentation Highlighting Preclinical Data from in vivo CAR T SG293 at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting
SEATTLE, April 27, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that an abstract ...
Sana Biotechnology Proxy statement: Proxy filing
Sana Biotechnology filed a proxy statement on April 24, 2026, providing details for shareholder voting and corporate governance matters.
Sana Biotechnology Proxy statement: Proxy filing
Sana Biotechnology filed a proxy statement on April 24, 2026, providing details for shareholder voting and corporate governance matters.
Sana Biotechnology price target raised to $7 from $6 at Wedbush
Wedbush analyst Martin Fan raised the firm’s price target on Sana Biotechnology (SANA) to $7 from $6 and keeps an Outperform rating on the shares. The firm notes Sana announced…
Sana Biotechnology announces SC451 strategic collaboration with Mayo Clinic
Sana Biotechnology (SANA) and Mayo Clinic announced a strategic collaboration to advance development of SC451, Sana’s investigational hypoimmune-modified pancreatic islet cell therapy for type 1 diabe...
Sana Biotechnology Slides: Corporate presentation
Sana Biotechnology has posted slides in relation to its latest quarterly earnings report, which was published on April 13, 2026.
Sana announces follow-up results from first-in-human study transplanting UP421
Sana Biotechnology (SANA) announced 14-month follow-up results from an investigator-sponsored, first-in-human study transplanting UP421, an allogeneic primary islet cell therapy engineered with Sana’s...
Sana Biotechnology Transcript: The Citizens Life Sciences Conference 2026
The conference highlighted advances in hypoimmune cell therapies for Type 1 diabetes, including a year-long successful human case and scalable manufacturing progress. In vivo CAR T cell programs are set for clinical trials this year, with human data expected by year-end.
Sana Biotechnology files automatic mixed securities shelf
17:22 EST Sana Biotechnology (SANA) files automatic mixed securities shelf
Sana Biotechnology reports Q4 EPS (16c), consensus (13c)
Cash, cash equivalents, and marketable securities as of December 31, 2025 were $138.4M compared to $152.5M as of December 31, 2024. The decrease of $14.1M was primarily driven by cash…